Related references
Note: Only part of the references are listed.The BRET technology and its application to screening assays
Johan Bacart et al.
Biotechnology Journal (2008)
A new small molecule inhibitor of estrogen receptor α binding to estrogen response elements blocks estrogen-dependent growth of cancer cells
Chengjian Mao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Structure of the intact PPAR-γ-RXR-α nuclear receptor complex on DNA
Vikas Chandra et al.
NATURE (2008)
Intermolecular interactions identify ligand-selective activity of estrogen receptor α/β dimers
Emily Powell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy
Karson S. Putt et al.
NATURE CHEMICAL BIOLOGY (2006)
Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells
Edmund C. Chang et al.
ENDOCRINOLOGY (2006)
Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET)
KDG Pfleger et al.
NATURE METHODS (2006)
Obtaining and screening compound collections: a user's guide and a call to chemists
PJ Hergenrother
CURRENT OPINION IN CHEMICAL BIOLOGY (2006)
Estrogen receptors alfa (ERα) and beta (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11
LA Helguero et al.
ONCOGENE (2005)
Estrogen receptor α and β subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells
A Gougelet et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Hsp90: an emerging target for breast cancer therapy
J Beliakoff et al.
ANTI-CANCER DRUGS (2004)
Development of a bioluminescence resonance energy-transfer assay for estrogen-like compound in vivo monitoring
E Michelini et al.
ANALYTICAL CHEMISTRY (2004)
A nonradiometric, high-throughput assay for poly(ADP-ribose) glycohydrolase (PARG): application to inhibitor identification and evaluation
KS Putt et al.
ANALYTICAL BIOCHEMISTRY (2004)
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Edward A. Sausville et al.
CURRENT CANCER DRUG TARGETS (2003)
An estrogen receptor (ER)α deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signaling in vivo
M Jakacka et al.
MOLECULAR ENDOCRINOLOGY (2002)
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats
MJ Egorin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
A Maloney et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2002)
Estrogen receptor-β potency-selective ligands:: Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues
MJ Meyers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway
M Jakacka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Pyrazole ligands:: Structure-affinity/activity relationships and estrogen receptor-α-selective agonists
SR Stauffer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
